Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Avenue Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Avenue Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Fortress Biotech, Inc. | 10% Owner | 439,733 | Jan 6, 2026 | 1 |
| Herskowitz Neil | Director | 97 | Dec 3, 2024 | 0 |
| Kranzler Jay D | Director | 559 | Nov 7, 2024 | 0 |
| Rosenwald Lindsay A MD | Director | 354,318 | Sep 25, 2024 | 0 |
| Oltmans Curtis Gale | Director | 49,020 | Sep 25, 2024 | 0 |
| Charles Faith L. | Director | – | Sep 25, 2024 | 0 |
| Jin David | Interim PFO and COO | 65,000 | Sep 25, 2024 | 0 |
| MacLean Alexandra | Chief Executive Officer | 170,000 | Sep 25, 2024 | 0 |
| Davidow Robert L | 10% Owner | 80,000Indirect | Dec 13, 2023 | 0 |
| InvaGen Pharmaceuticals, Inc. | 10% Owner | 0 | Oct 13, 2022 | 0 |
| Lu Lucy | President, CEO | 748,949 | Dec 20, 2021 | 0 |
| Vazzano Joseph Walter | Chief Financial Officer | 165,757 | Dec 20, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 3, 2024 (view filing) | Dec 2 | 1 day | Herskowitz NeilDirector | SSaleCOMMON STOCK, PAR VALUE $0.0001 | −23 | $2.00 | −$46 | −19.2%97 after | |
| Nov 7, 2024 (view filing) | Nov 5 | 2 days | Kranzler Jay DDirector | SSaleCOMMON STOCK, PAR VALUE $0.0001 | −61 | $2.24 | −$136.64 | −9.8%559 after | |
| Oct 1, 2024 (view filing) | Sep 27-30 | 4 days | Kranzler Jay DDirector | PPurchaseCOMMON STOCK, PAR VALUE $0.0001 | +500 | $2.50 | +$1.25K | +416.7%620 after | 2 lots |
| Dec 13, 2023 (view filing)4:02 PM ET | Dec 11 | 2 days | Davidow Robert L10% Owner | SSale | −264.0K | $0.14 | −$37.0K | −27.9%681.0K after | |
| Dec 13, 2023 (view filing)4:02 PM ET | Dec 11 | 2 days | Davidow Robert L10% Owner | SSale | −353.0K | $0.1405 | −$49.6K | −81.5%80.0K after | 5 lots |
| Sep 12, 2023 (view filing) | Sep 8 | 4 days | Rosenwald Lindsay A MDDirector | PPurchase | +348.7K | $0.72 | +$251.0K | +6,178.9%354.3K after | |
| Sep 12, 2023 (view filing) | Sep 8 | 4 days | Fortress Biotech, Inc.10% Owner | PPurchase | +418.4K | $0.72 | +$301.3K | +68.1%1.03M after | |
| Oct 13, 2022 (view filing) | Oct 11 | 2 days | InvaGen Pharmaceuticals, Inc.10% Owner | SSaleCommon Stock, par value $0.0001 per share | −388.9K | $7.71 | −$3.00M | −100.0%0 after | |
| Sep 15, 2021 (view filing) | Sep 15 | Same day | Vazzano Joseph WalterChief Financial Officer | SSale | −7.16K | $1.62 | −$11.6K | −9.9%65.3K after |